Pretax income is the income that a company earns before paying income taxes. Cadrenal Therapeutics's pretax income for the
three
months ended in Mar. 2024 was $-1.66 Mil.
Its pretax income for the trailing twelve months (TTM) ended in Mar. 2024 was $-4.85 Mil.
Cadrenal Therapeutics's pretax margin was %.
Cadrenal Therapeutics Pre-Tax Income Historical Data
The historical data trend for Cadrenal Therapeutics's Pre-Tax Income can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Competitive Comparison of Cadrenal Therapeutics's Pre-Tax Income
For the Biotechnology subindustry, Cadrenal Therapeutics's Pre-Tax Income, along with its competitors' market caps and Pre-Tax Income data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Cadrenal Therapeutics's Pre-Tax Income Distribution in the Biotechnology Industry
For the Biotechnology industry and Healthcare sector, Cadrenal Therapeutics's Pre-Tax Income distribution charts can be found below:
* The bar in red indicates where Cadrenal Therapeutics's Pre-Tax Income falls into.
Cadrenal Therapeutics Pre-Tax Income Calculation
This is the income that a company earns before paying income taxes.
Cadrenal Therapeutics's Pretax Income for the fiscal year that ended in Dec. 2023 is calculated as
Pre-Tax Income for the trailing twelve months (TTM) ended in Mar. 2024 adds up the quarterly data reported by the company within the most recent 12 months, which was $-4.85 Mil.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Cadrenal Therapeutics (NAS:CVKD) Pre-Tax Income Explanation
Cadrenal Therapeutics's Pretax Margin for the quarter that ended in Mar. 2024 is calculated as
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Cadrenal Therapeutics Pre-Tax Income Related Terms
Thank you for viewing the detailed overview of Cadrenal Therapeutics's Pre-Tax Income provided by GuruFocus.com. Please click on the following links to see related term pages.
Cadrenal Therapeutics (Cadrenal Therapeutics) Business Description
Cadrenal Therapeutics Inc is focused on developing a novel therapy with orphan drug indication, tecarfarin, for the prevention of systemic thromboembolism (blood clots) of cardiac origin in patients with end-stage renal disease (on dialysis) and atrial fibrillation (irregular heartbeat) or AFib. Tecarfarin is an anticoagulant designed using a drug design process that targets a different pathway than most commonly prescribed drugs for the treatment of thrombosis and AFib.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
Portfolio Contest
CVKD has been successfully added to your 